Image credits: AP
As COVID-19 vaccination drive is ongoing in the country, Pfizer’s CEO Mr. Albert Bourla on Tuesday said that the vaccine is in the final stages of getting approved in India. Now talking about the progress of Pfizer vaccine approval in India, CEO Albert Bourla said that, “I hope very soon we will finalize an agreement with the government.”
Besides this, a study at Lancet has said Pfizer and AstraZeneca vaccines will provide good protection against the new Delta variant of coronavirus, which was first identified in India, but it has doubled the risk of hospitalization as compared with the Alpha variant which was first found in the UK.
The team has surveyed over 19,543 confirmed SARS-CoV-2 infections over the period of interest, around 377 were admitted to hospital for COVID-19 in Scotland. Around 7,723 community cases and 134 hospitalizations were seen to be affected by the Delta variant of coronavirus.
The study found that the Pfizer vaccine has recommended around 92 per cent protection against the Alpha variant and 79 per cent against the Delta strain within the span of two weeks after the second dose. For AstraZeneca’s vaccine, there was about 60 per cent protection against Delta as compared to 73 per cent for Alpha variant, the researchers said according the survey.
The analysts have also researched that two doses of vaccine can provide much better protection against the Delta variant compared to a single dose of Pfizer.